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I
 Tropical forests are one of the most diverse and endangered habitats on earth. They have also been portrayed 
as a source of future pharmaceuticals, yet finding useful compounds can be both scientifically and politically 
challenging. Increasingly, over the past decade, the potential value of medicinal compounds derived from 
plants, microorganisms, and animals has been proposed as a tangible benefit of biodiversity, and therefore a 
basis for promoting its preservation. Ecological theories of plant defense can increase the probability of dis­
covering compounds with activity in bioassays against human disease targets. In addition, conducting 
research in tropical countries with local scientists provides immediate and lasting benefits for the sustainable 
use of biodiversity. This new approach to drug discovery has been effective in identifying bioactive leads. It is 
both an important step towards understanding the medicinal value of biodiversity, and a practical way to 
link drug discovery with conservation.
Front Ecol Environ  2003; 1(8): 4 2 1 -4 2 8
The conversion of natural habitats for human use rep^ resents the primary driving force in the loss of biology 
ical diversity; 40-50% of the earth’s land surface is already 
degraded by humans and the fate of remaining biodiver^ 
sity will probably be determined in the next few decades 
(Vitousek et al 1997; Sala et al 2000; Tilman et al 2001). 
Given this massive, rapid assault, multiple approaches 
with immediate impacts are necessary to protect species^ 
rich habitats (Pimm 2001). One approach, often called 
“use it or lose it”, attempts to identify a habitat’s economic 
value so that protecting biodiversity provides greater ben^
In a nutshell:
• Drug discovery is a nondestructive use of biodiversity that ere- 
ates incentives to conserve wildlands
• The typical approach with royalties as the only incentive is 
insufficient, as the probability of marketing a drug is low
• Conducting a portion of drug discovery in biodiversity-rich 
nations guarantees immediate benefits even if royalties never 
materialize, and promotes conservation
• The use of ecological theory on plant chemical defenses shows 
that young leaves are an excellent source of compounds active 
against human disease targets
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efits than alternative uses (Janzen 1997; Janzen 1999; 
Balvanera et al 2001). For example, many ecosystem ser^ 
vices have been shown to have greater value than logging 
or agriculture (Daily et al 2000; Beattie and Ehrlich 2001; 
Cork 2002; Daily and Ellison 2002; Balmford et al 2003; 
Rosenzweig 2003). Bioprospecting, the search for chemi^ 
cals or genes with medicinal or agricultural applications, is 
another sustainable and ecologically gentle use of biodi^ 
versity that can promote conservation.
The Convention on Biological Diversity, presented in 
1992 at the Earth Summit in Rio de Janeiro, promotes the 
use and conservation of biological diversity, and requires 
the fair and equitable distribution of benefits. While bio­
prospecting is widely cited as a way to give value to biodi^ 
versity, its effectiveness has been slowed by the difficulty 
of providing immediate benefits from the use of genetic 
resources. In fact, bioprospecting in biodiversity^rich 
countries is still in its infancy. In 1998, we initiated a pro­
ject called “Ecologically Guided Bioprospecting in 
Panama”, with the aims of discovering novel agents that 
promote human health in a manner consonant with the 
benefit^sharing provisions of the C onvention on 
Biological Diversity, and spurring biodiversity^rich coun­
tries to initiate their own conservation measures. The 
ongoing project (www.icbgpanama.org) is an Inter^ 
national Cooperative Biodiversity Group (ICBG) funded 
by the National Institutes of Health, the National Science 
Foundation, and the US Department of Agriculture 
(Kursar e ta l  1999).
Natural products have been a rich source of therapeutic 
agents, many of which come from higher plants 
(Kinghom and Balandrin 1993; Balick et a l 1996; Grifo 
and Rosenthal 1997). In some areas of medicine, espe^
© The Ecological Society of America www.frontiersinecology.org
Plant collection strategies for drug discovery PD Coley et al.
daily cancer, plants continue to provide novel drug treat' 
ments such as taxol and camptothecan (Shu 1998; Cragg 
and Newman 1999; Mann 2002). Even so, tropical plants 
are under-investigated as sources of new medicines. 
Conventionally, pharmaceutical companies have con­
tracted with botanists who make random collections of 
dried plant tissue for testing in proprietary bioassays. Less 
commonly, ethnobotanical information has been used to 
guide collections (Kingston et al. 1999; Lewis et al 1999; 
Schuster et al 1999; Cox 2001). A  third approach, still in 
its infancy, uses ecological information to discover useful 
natural products (Reid et al 1993; Beattie and Ehrlich 
2001). For example, we spent 4 years collecting leaves at 
numerous sites in Panama to determined levels of activity 
in bioassays against cancer, HIV, and tropical diseases. 
Here we discuss the inclusion of ecological theories about 
plant defense in the design of collection strategies for bio­
prospecting.
■  Using plant defense theory
The evolutionary “arms race” between herbivores and 
plants has created a huge diversity of plant secondary 
metabolites (Ehrlich and Raven 1964; Kareiva 1999; 
Thompson 1999; Rausher 2001), and nowhere in the 
world are these biotic interactions more intense than in 
tropical rainforests (Price et a l 1991). The high biotic 
pressure in the tropics has led to higher levels of chemical 
defense as well as a greater diversity of compounds in 
tropical species, as compared to temperate ones (Gentry 
1993; Coley and Barone 1996; Coley and Kursar 1996). 
For example, an extensive survey of the distribution and 
activity of alkaloids showed that they are more common 
and more toxic in the tropics (Levin 1976; Levin and 
York 1978). All other classes of compounds that have 
been surveyed exhibit similar patterns (Coley and Aide 
1991; Coley and Barone 1996).
Figure !♦ Young leaves of Panamanian woody plants.
Despite the many drugs obtained from plants in the past, 
success rates could be greatly improved by incorporating 
ecological knowledge. By applying our current under­
standing of plant defenses and herbivory, we developed a 
collection strategy aimed at enhancing the discovery of 
useful pharmaceuticals. To test our ideas, we collected 
leaves in protected wildlands throughout Panama and pre­
pared extracts from them while still fresh. We evaluated 
activity in five in vitro bioassays against human disease: 
three cancer cell lines (breast MCF-7, lung H-460, and 
central nervous system SF-268); HIV; and three tropical 
disease cell lines, leishmaniasis (Leishmania mexicana), 
malaria (Plasmodium falciparum) and Chagas’ disease 
(Trypanosoma cruzi). For the tropical disease bioassays, 
new methodologies were developed in Panama, as stan­
dard methods using radioactive reagents are not possible 
in developing nations. Extracts were considered highly 
active if they killed or inhibited growth in the target cells 
(for methods see Web only materials).
■  Tests of plant defense theory 
Activity is greater in young leaves
Most conventional drug discovery programs make collec­
tions of mature leaves, roots, or other tissues. We pre­
dieted that young, expanding leaves would contain more 
active secondary metabolites than mature leaves (Figure
1) and thus be more active in bioassays. Mature leaves of 
tropical plants are tough because of the high lignin and 
cellulose contents of their thick cell walls (Lucas et al 
2000). Although toughness is one of the most effective 
defenses against herbivores (Coley 1983; Lowman and 
Box 1983; Coley and Kursar 1996), it has no therapeutic 
or agricultural potential. In contrast, young leaves cannot 
toughen until the cells finish expanding, leaving them 
highly vulnerable to herbivores. In the 
tem perate zone, most young leaves 
emerge early in the spring while herbi­
vore populations are low. Perhaps 
because of this, young temperate leaves 
are not chemically well defended (Coley 
and Aide 1991).
In the humid tropics, however, her­
bivory on young leaves is extremely high 
all year round, accounting for 70% of the 
lifetime damage to shade-tolerant species 
(Coley and Aide 1991). This strong 
biotic pressure has apparently selected for 
numerous anti-herbivore defenses in 
young leaves, including investments in 
secondary metabolites (Coley and Barone 
1996; Kursar and Coley 2003). For exam­
ple, concentrations of terpenes (toxic 
hydrocarbons) and alkaloids (a particu­
larly important group of medicinal com-
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pounds) are significantly higher in young tropical leaves as 
compared to mature ones (Crankshaw and Langenheim 
1981; Langenheim et a l 1986; Kursar et al 1999).
We evaluated the activity in our bioassays of methanolic 
extracts made from young and mature leaves. Young leaves 
had greater activity than mature leaves in almost every dis­
ease bioassay (Figure 2; Web Table 1). To facilitate compar­
isons across bioassays with different means and variances, 
results were normalized so the mean of all extracts tested in 
a particular bioassay equaled zero and the variance equaled 
one (Z-score transformation). In almost all bioassays, the 
average value for young leaves was greater than zero, indi­
cating above-average activity. In contrast, values for mature 
leaves were less than zero, indicating below-average activ­
ity. This pattern held when bioassay results were compared 
for young and mature leaves collected from the same plant 
(Figure 2, top) or for all samples (Figure 2, bottom). In addi­
tion, a higher percentage of young leaf samples were highly 
active and thus merited further investigation for therapeu­
tic potential (Web Figure 1).
Young leaves have unique compounds
We predicted that young leaves, in addition to higher 
levels of chemical defense, would also have different sec­
ondary metabolites than mature leaves. Because young 
leaves cannot toughen, selection should favor additional 
chemical defenses specific to this developmental stage 
(Coley and Kursar 1996). Once leaves stop expanding 
and toughen, these compounds may no longer be neces­
sary and could be catabolized (metabolically broken 
down) for other purposes. Many secondary metabolites 
may thus only be present in young leaves.
In a survey of 18 Panamanian woody species, we con­
trasted the number of alkaloids present in young and 
mature leaves of the same plants using thin layer chro­
matography and DragendorfPs reagent (Kursar et al 
1999). Ten out of 18 species had alkaloids that were pre­
sent only in the young leaves, while only three species had 
alkaloids unique to mature leaves. Among the 24 alkaloids 
unique to either young or mature leaves, 71% were found 
only in young leaves and 29% only in mature leaves. High 
performance liquid chromatography analyses of the major 
peaks from alkaloidal extracts of young and mature leaves 
of 23 species showed 60 peaks unique to young leaves and 
40 unique to mature leaves.
To date we have pursued isolation of compounds from 
15 species that were highly active in our bioassays. In two 
cases, the active compounds were present in both young 
and mature leaves, but in 13 species the compound was 
absent or found in such low concentrations in mature 
leaves that it was only possible to detect activity and 
purify it from young leaves (Bonetto et al 2003; Cherigo et 
al 2003; Hussein et al 2003; Montenegro et a l 2003; 
Mendoza et al. 2003). We recently obtained a provisional 
patent for several alkaloids, isolated only from young 
leaves, that are active against Leishmania, the parasite
Figure 2. Activity of extracts from young and mature leaves in 
bioassays, (top) Paired analysis of species for which we have 
bioassay data on young and mature leaves from the same plant. 
(Species were not tested in every bioassay.) We tested 101 species 
for activity against cancer, 58 for malaria, 76 for Chagas’ disease 
(extracellular form), 18 for Chagas’ disease (intracellular form), 
40 for leishmaniasis (promastigote cell type), and 84 for 
leishmaniasis (amastigote cell type) . A  paired t-test on raw values 
was significant (P < 0.05) for H460, MCF7, and Chagas’ 
(extracellular). Data for HIV are not included as they are scored 
as active or inactive, (bottom) Analysis of all samples. Extracts 
from young leaves were significantly more active than those from 
mature (nonparametric A NOVA, P < 0.002). We tested 1077 
species against cancer, 443 for malaria, 717 for Chagas’ 
(extracellular), 277 for Chagas’ (intracellular), 950 for 
leishmaniasis (promastigotes), and 158 for leishmaniasis 
(amastigotes). A  two-sided Wilcoxon test on Z-scores of young 
and mature leaves was significant (P < 0.05) for H460, MCF7, 
malaria, and both forms of Chagas’.
that causes leishmaniasis. There is a great deal of chemical 
diversity in young leaves, and this promising source 
remains largely untapped (see Web material).
Greater activity in shade-tolerant species
Plant defense theory predicts that the mature leaves of 
slow-growing, shade-tolerant species should have better 
chemical and physical protection than mature leaves of
423
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Figure 3. Activity of young and mature leaves from shade-tolerant and gap- 
specialist species (± SE). Values with different letters are significantly different at 
P < 0.05 (Duncan Multiple Range Test, A N O V A ). A  higher value for the Z-score 
indicates greater activity averaged across all bioassays. There were 3612 activity 
results, resulting from testing different plant species and leaf ages in multiple 
bioassays.
gap specialists. This prediction was con­
firmed by our bioassay results (Figure 3). 
The extremely low rates of herbivory on 
mature shade-tolerant leaves (Marquis 
and Braker 1994; Coley and Barone 
1996) can therefore be attributed to 
greater investment in both physical and 
chemical defenses.
The activity in young leaves from gap 
specialists and shade-tolerant species did 
not differ. All young leaves were highly 
active, and similar in activity to mature 
leaves of shade-tolerant species. The 
mature leaves of gap species were the least 
active. These results are consistent with 
theory and field data on herbivory (Coley 
1983; Coley et al 1985; Kursar and Coley 
2003; Web Table 2).
Plant growth form weakly correlated 
with activity
fast-growing species found in the high-light conditions of 
tree-fall gaps (Coley et a l 1985). Because replacing lost 
leaves entails a greater cost in low-resource environ­
ments, shade-tolerant species have well defended leaves 
that suffer little herbivory (Grime 1979; Coley 1983; 
Coley 1988; Reich et a l 1999; Wright et a l 2002). 
Extracts from the mature leaves of shade-tolerant species 
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Plant growth rates, leaf age, and leaf lifes­
pans should be good predictors of invest­
ment in secondary metabolites, but growth form per se 
should not. However, others have argued that particular 
forms may be a rich source of potential drugs. For exam­
ple, it has been predicted that epiphytes (Bennett 1992) 
and lianas (Hegarty et a l 1991) should be especially good 
sources of active compounds. Our data suggest that nei­
ther were particularly active (Figure 4). Extracts from 
shrubs and trees were the most active. Palms were the 
poorest source of active extracts, 
undoubtedly due to the extremely fibrous 
nature of both young and mature leaves. 
There was a significant effect of growth 
form on activity (Web Table 1). 
However, when palms were excluded 
from the analysis, growth form was only 
marginally significant (P = 0.06), suggest­
ing that growth form effects were domi­
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Figure 4* Activity of extracts from species with different growth forms (± SE). 
Values with different letters are significantly different at P < 0.05 (Duncan Multiple 
Range Test, ANOVA). A  higher value for the Z-score indicates greater activity 
averaged across all bioassays. Sample sizes (resulting from testing different leafages 
in multiple bioassays) were: 1078 for shrubs, 2738 for trees, 744 for herbs, 158 for 
ferns, 373 for lianas, 438 for vines, 161 for epiphytes, and 70 for palms.
■ Phylogenetic patterns of activity
One approach often used in drug discov­
ery is to focus on families known to have 
unusual chemical structures (eg 
Euphorbiaceae) or to contain classes of 
known bioactive compounds such as 
alkaloids (eg Rubiaceae, Solanaceae, 
Fabaceae, and Apocynaceae). Although 
there is some justification for this 
approach (Barclay and Perdue 1976), our 
data do not provide strong support. For 
example, Euphorbiaceae ranked 105 out 
of 147 families we tested. The four alka-
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Figure 5♦ The activity and phybgenetic relationships among 34 orders of 
flowering plants. Units of activity are Z-scores averaged across all bioassays. 
Values with different letters are significantly different a t?  <0.05 (Duncan 
Multiple Range Test, ANOVA). The study species were grouped into six 
clades: (I) ferns; (2) monocots; (3) Magnoliid complex (Magnoliales, Laur- 
ales, Piperales) plus Chloranthales; (4) basal tricolpates (Ranunculales, Pro- 
teales), Gunnerales, Caryophyllid clade (Dillenales, Caryophyllales), San- 
tables, and Vitales; (5) rosids (Myrtales, Celestrales, Malpighiales, 
Oxalidales, Fabales, Rosales, Curcurbitales, Fagales, Malvales and Sapin- 
dales); and (6) asterids (Ericales, Gentiarudes, Lamiales, Sobnales, Aqui- 
foliates, Apiales, Aster ales and Dipsacales). The nomendature and phyb­
genetic reconstruction folbw those of Judd et al. (2002) and the Angiosperm 
Phybgeny Group of the Missouri Botanical Garden (Stevens PF, Version 4 , 
May 2003, www.mobot.org/MOBOT/research/Apweb)
loid-rich families showed intermediate activity, 
with ranks ranging from 28 to 90. In fact, the 
most active families were small and rather poorly 
studied from a chemical or pharmacological per­
spective. The families are listed in Web Table 3, 
in order of decreasing activity in our bioassays.
Plant families differed considerably in their 
activity and there was no interaction between 
family and bioassay type (Web Table 1), suggest­
ing that the activity level for a given family is 
similar across many different disease targets.
We also tested the idea that the more recently 
evolved species would have greater activity, as 
might be predicted by the chemical “arms race” 
(Ehrlich and Raven 1964; Kareiva 1999; 
Thompson 1999; Rausher 2001). This was not 
strongly supported, as the basal angiosperms (the 
Magnoliids and Chloranthales) were the most 
active, followed by the more derived Asterids and 
Rosids (Figure 5). Monocots were least active, 
perhaps because parallel leaf venation permits 
extensive toughening early in leaf development, 
resulting in less attack by herbivores and less 
selection for chemical defense. Overall, we found 
a strong phylogenetic signature, with some clades 
being clearly more active than others.
■ Ecological insight in drug discovery
Application of plant defense theory allowed us to 
collect plant species and tissues with greater 
activity in bioassays. The ecological criteria used 
to collect organisms must be easy to implement 
in the field and broad enough to generate a reasonable 
number of samples for bioassays. Ecological approaches 
should also be based on sound science, so that increases 
in active extracts justify the extra effort of selecting sam­
ples. The ecological criteria outlined in this paper arose 
from work in Africa, Southeast Asia, and Panama (Coley 
and Kursar 1996; Kursar and Coley 2003) and should 
therefore be applicable in tropical forests worldwide.
W hen research leads to the commercialization of a drug, 
large quantities of the compound are required. The pre­
ferred option is synthesis of the compound, a derivative, or 
an analog. These options still provide royalties to the 
source countries, through patents or contract stipulations 
that ensure equitable benefit sharing. If synthesis is not 
cost effective, then the plants can be grown in planta­
tions, providing an alternative “cash crop” for the host 
country. Legal agreements as well as public pressure can 
prohibit the destructive harvesting of wild plants as a 
source.
■ Drug discovery as a conservation tool
Drug discovery has been portrayed as a way to combine 
research to improve human health with the sustainable
use of biodiversity (Rosenthal et al. 1999). Nevertheless, 
the effective application of bioprospecting to conserva­
tion remains a fundamental, unsolved problem. A key 
criticism from conservationists and economists is that 
royalties are the sole source of benefits provided to the 
host country in most benefit-sharing arrangements. 
Unfortunately, the probability of a drug making it to the 
market is extremely low, so developing nations are 
unlikely to receive any royalties from uses of their biodi­
versity. The challenge, therefore, is to provide immediate 
and guaranteed benefits even if royalties are not forth­
coming.
A solution becomes apparent upon recognizing that the 
research and development pyramid underlying the suc­
cessful development of a drug is based upon many basic 
but essential discoveries, a tiny fraction of which result in 
a product. Many of these inventions originate from dis­
coveries that were initially made in academia or by small 
companies. Also, large sums are invested in research and 
development of drugs. Worldwide pharmaceutical invest­
ment in research and development is estimated at $27-43 
billion per year (Agnew 2000); about one third of that is 
spent on research that could be carried out in developing 
countries, including extraction, synthesis, in vitro bioas-
425
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says, and activity and efficacy testing in vertebrate models 
(ten Kate and Laird 1999). In addition to pharmaceutical 
companies, governments and non-profit organizations 
also provide substantial support for research in biodiver­
sity and drug discovery.
If a part of these huge investments by industry, govern­
ments of developed nations, and NGOs could be redi­
rected towards bioprospecting research in the source 
country, then biodiversity-rich countries would receive 
immediate and guaranteed benefits from the non-destruc­
tive use of their natural resources. If only a fraction of the 
drug-discovery research were conducted in developing 
nations, this would provide many educational and job 
opportunities. For example, in our NIH-funded project, 
substantial results have been obtained with an investment 
of only $500 000 per year in Panama, a country of 3 mil­
lion people (Figure 6). We are using this base to forge new 
collaborations with pharmaceutical companies and to 
attract additional international funding. A similar out­
come could be derived in many of the biodiversity-rich 
nations of the world with an investment that would not be 
prohibitive.
For bioprospecting to have a positive impact on conser­
vation, immediate benefits must first be realized by the 
host country. While they must be included in legal agree­
ments, royalties are unlikely to materialize. However, one 
does not need to find a drug in order to link bioprospect­
ing to conservation. By conducting all of the research in
Figure 6. (left) Nayda Flores, 1CBG project’s botanist, collects 
leaves in protected forests in Panama, (right) Dr Luz Romero and 
assistant Yolanda Corbett conduct a bioassay to determine activity 
of leaf extracts against Leishmania mexicana in Panama.
Panama, we circumvent the issue of uncertain royalties 
and provide immediate and lasting benefits in the form of 
training, employment, technology transfer, and infrastruc­
ture development (Capson et a l 1996; Kursar et al 1999). 
These benefits provide an important but generally 
neglected mechanism for demonstrating the value of 
intact forests to Panamanians. Furthermore, the entire 
research effort is funded by foreign monies, and requires 
no investment by the country’s government. In principle, 
very similar benefits are provided by the National 
Biodiversity Institute in Costa Rica, the National 
Commission on Biodiversity Use and Knowledge of 
Mexico, the Brazilian Program of Molecular Ecology for 
the Sustainable Use of Amazon Biodiversity, the Ibero- 
American Program of Science and Technology Develop­
ment, and a number of bioprospecting companies in Brazil 
such as Extracta, Chamma da Amazonia, and Crodama- 
zon. The actual contributions that such efforts may make 
towards conservation are enmeshed in politics, and evalu­
ating impacts on conservation is beyond the scope of this 
paper. Nevertheless, the broad awareness of, and support 
for, their missions suggest that these in-country bio­
prospecting projects generate considerable incentive for 
conservation.
The first step towards effectively linking bioprospecting 
and conservation is to ensure the host country receives 
immediate benefits from the use of its biodiversity. In 
Panama we have tried to use bioprospecting as a conserva­
tion tool by providing tangible benefits, and after only 5 
years, our efforts have been acknowledged by the govern­
ment, the national university, the public, and the press. A 
second key step is to influence policy and public percep­
tion towards conservation. Several of our team members 
encouraged the government to recognize the value of
www.frontiersinecology.org © The Ecological Society of America
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Panama’s unique biodiversity and to initiate the Institute 
of Advanced Scientific Investigations and High 
Technology, a research institute with a substantial bio­
prospecting component. The National Authority of the 
Environment (ANAM) has called upon us with increas­
ing frequency to provide technical assistance, and our 
inventories of plants and insects have been helpful in 
establishing management plans for protected areas. As 
part of the ICBG project, we also recently played an 
instrumental role in helping ANAM  apply for UNESCO 
World Heritage Site status for Coiba National Park and 
surrounding areas (270 125 ha in all), thereby increasing 
the probability of effective protection for this unique 
marine and terrestrial habitat.
Thus, we are using several approaches to link bio­
prospecting, sustainable use, and economic development 
with the preservation of Panama’s biodiversity. Although 
bioprospecting can only be one of many simultaneous 
efforts to promote conservation, it is compatible with 
other non-destructive uses of biodiversity, such as eco­
tourism and ecosystem services.
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